# Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

> **NCT01902160** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 3 (actual)

## Conditions studied

- Recurrent Adult Hodgkin Lymphoma

## Interventions

- **DRUG:** Brentuximab Vedotin
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT01902160
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2015-05
- **Final completion:** —
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2015-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01902160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01902160, "Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01902160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*